GlassScriptPhysician profile
Pravinchandra P Patel
NPI 1124098603
$16,642.86
in general payments reported to CMS, 2019-2025
58 companies · $2,648 in 2025
The $2,648 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,425 · 2020: $1,825 · 2021: $2,787 · 2022: $2,952 · 2023: $2,525 · 2024: $2,480 · 2025: $2,648.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,496 · Travel and Lodging: $158.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,496.10 |
| Travel and Lodging | $157.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,530.95 | 2019-2025 | Farxiga, Airsupra, Lokelma |
| Glaxosmithkline, LLC. | $1,950.04 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $1,716.93 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $924.89 | 2019-2025 | Spravato, Xarelto |
| Novo Nordisk INC | $854.17 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $808.11 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $755.29 | 2019-2024 | Ofev, Stiolto Respimat, Spiriva Respimat |
| Lilly USA, LLC | $695.77 | 2020-2024 | Mounjaro, Jardiance, Zepbound |
| Abbott Laboratories | $382.33 | 2020-2025 | Freestyle Libre 3, Eterna |
| Mylan Specialty L.P. | $359.28 | 2022-2024 | Yupelri |
| Sumitomo Pharma America, INC. | $325.63 | 2023-2025 | Gemtesa |
| Ardelyx, INC. | $306.70 | 2024-2025 | Ibsrela |
| Esperion Therapeutics, INC. | $300.31 | 2020-2025 | Nexletol |
| Pfizer INC. | $298.61 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $276.14 | 2019-2023 |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pravinchandra Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.